- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04591613
Late Clinical Events Associated With COVID-19 Infection (COCO-LATE)
Late Clinical Events Associated With COVID-19 Infection: Multicenter Cohort
Several publications document the occurrence of symptoms that persist or occur late.
The identification of the observed clinical manifestations and their clinical and paraclinical description are essential to better understand the natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible late manifestations, and to identify potential management options for patients.
Since this type of event is infrequent, a large-scale national multicenter cohort study focusing on symptomatic patients is needed.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Several publications document the occurrence of symptoms that persist or occur late, more than 3 weeks after the first clinical manifestations of an SARS-COV2 infection. These manifestations may be related to thromboembolic or inflammatory complications, superinfections, or other mechanisms not yet well understood, including potentially related to the persistence of SARS-COV2. The identification of the observed clinical manifestations and their clinical and paraclinical description are essential to better understand the natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible late manifestations, and to identify potential management options for patients.
Since this type of event is infrequent, a large-scale national multicenter cohort study focusing on symptomatic patients is needed. In parallel, the prevalence of the main symptoms observed more than 3 weeks after the onset of a COVID-19 will be estimated through partnerships with existing cohort studies in the general population or in the population followed for COVID-19, still symptomatic or not at 3 weeks of infection.
Longitudinal implementation of bio-libraries will allow this cohort to also constitute a bridge between clinicians and researchers.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Olivier ROBINEAU, MD PhD
- Numéro de téléphone: 0320694949
- E-mail: orobineau@ch-tourcoing.fr
Lieux d'étude
-
-
-
Auxerre, France
- Recrutement
- CH Auxerre
-
Caen, France
- Recrutement
- CHU Caen
-
Lille, France
- Recrutement
- CHRU Lille
-
Melun, France
- Recrutement
- CH Melun Marc Jacquet
-
Nemours, France
- Recrutement
- CH Sud Seine et Marne
-
Paris, France
- Pas encore de recrutement
- AP-HP Hôpital Hôtel-Dieu
-
Saint-Priest-en-Jarez, France
- Recrutement
- CHU de Saint-Etienne
-
Tourcoing, France
- Recrutement
- CH Tourcoing
-
Tours, France
- Recrutement
- Chru Tours
-
Vandœuvre-lès-Nancy, France
- Recrutement
- CHRU NANCY
-
Vannes, France
- Recrutement
- Centre Hospitalier Bretagne Atlantique
-
-
-
-
-
Cayenne, Guyane Française
- Recrutement
- CH André Rosemon de Cayenne
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
History of symptomatic CoV-2-SARS infection as defined by :
o Positive RT-PCR SARS-CoV-2 RT-PCR result OR positive SARS-CoV-2 serology
o Associated with at least one event : x Anosmia occurring after February 2020 x OR COVID 19 evocative scanner x OR ≥ 2 contemporary symptoms of the virological sample from: asthenia, cough, dyspnea, fever, myalgia, dysgeusia, diarrhea AND not present prior to diagnosis
- AND persistence of at least one symptom present in the first 3 weeks of a COVID-19, more than 8 weeks away from the first symptoms of COVID-19. OR late onset of at least one new symptom a minimum of 3 weeks and a maximum of 6 months after the first symptoms of a CoV-2 SARS infection.
- First symptoms less than 6 months old on the day of inclusion
- To benefit from a State Health Insurance or Medical Aid plan
- Have signed an informed consent for inclusion.
Exclusion Criteria:
- Minor patient
- Patient under protection of justice
Patient who required intensive care management :
- more than 5 days
- OR requiring orotracheal intubation
- OR having required high flow ventilation (optiflow)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Standardized clinical and paraclinical follow-up
Standardized clinical and paraclinical follow-up will be offered in one of the referring investigator centers. Patients will be able to benefit from additional biological samples. Questionnaires will be completed by the patient or with the help of clinical research staff in paper format. All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID. Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits. Total serum, plasma and naso-paaryngeal samples will be collected. |
Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
Total serum, plasma samples will be collected
All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Clinical description of asthenia
Délai: At the end od the study, an average of 22 months
|
Describe the frequence of asthenia between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
|
Clinical description of dyspnea
Délai: At the end od the study, an average of 22 months
|
Frequence of dyspnea between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
|
Clinical description of thoracic disorders
Délai: At the end od the study, an average of 22 months
|
Frequence of thoracic disorders between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
|
Clinical description of neurological disorders
Délai: At the end od the study, an average of 22 months
|
Frequence of neurological disorders between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
|
Clinical description of anosmia
Délai: At the end od the study, an average of 22 months
|
Frequence of anosmia disorders between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Olivier ROBINEAU, MD PhD, CH Tourcoing
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- RIPH_2020_09
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .